The cyclic nucleotide phosphodiesterases (PDEs) are intracellular enzymes that catalyze the hydrolysis of 3,′5′-cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), to their corresponding 5′nucleotide monophosphates. These enzymes play an important role in controlling cellular concentrations of cyclic nucleotides and thus regulate a variety of cellular signaling events. PDEs are emerging as drug targets for several diseases, including asthma, cardiovascular disease, attention-deficit hyperactivity disorder, Parkinson's disease, and Alzheimer's disease. Although biochemical assays with purified recombinant PDE enzymes and cAMP or cGMP substrate are commonly used for compound screening, cellbased assays would provide a better assessment of compound activity in a more physiological context. The authors report the development and validation of a new cell-based PDE4 assay using a constitutively active G-protein-coupled receptor as a driving force for cAMP production and a cyclic nucleotide-gated cation channel as a biosensor in 1536-well plates. (Journal of Biomolecular Screening 2008:609-618) 
INTRODUCTION
C YCLIC NUCLEOTIDE PHOSPHODIESTERASES (PDEs) hydrolyze 3,′5′-cyclic nucleotides, including cAMP and cGMP, to their corresponding 5′-nucleotide monophosphates AMP and GMP. Both cAMP and cGMP are important second messengers coupling to the G-protein-coupled receptors (GPCRs) and mediate the responses of a variety of hormones and neurotransmitters. PDEs are responsible for terminating cellular responses to hormones and neurotransmitters, which is critical for maintaining proper intracellular signaling events. There are 11 families of PDEs from 21 different genes. 1, 2 Each PDE family is distinguished functionally by unique enzymatic characteristics and pharmacological profile as well as distinct tissue distribution and cellular expression patterns. 3, 4 Because PDEs regulate a variety of cellular functions, they have become important drug targets for the treatment of several diseases including sexual dysfunction, asthma, chronic obstructive pulmonary disease, neurodegenerative diseases (Parkinson's disease and Alzheimer's), diabetes, vascular diseases, osteoporosis, cancer, and rheumatoid arthritis. 2, 5, 6 PDE4 isoenzymes specifically hydrolyze cAMP and are therapeutic targets for the treatment of several inflammatory disorders.
A number of biochemical assays are available for screening of PDEs that use purified recombinant enzymes and cAMP or cGMP as the substrate. However, a cell-free assay environment may not faithfully reproduce the physiological environment of the cell due to differences in buffer components, pH, and cofactors, among others. In addition, compounds active in enzyme assays are often inactive in disease models due to poor cell membrane permeability, intracellular metabolism, or active sites with highly polar groups. 7 Therefore, inhibitors identified from enzyme assays usually need to be optimized in cell-based assays before proceeding to animal model studies. A cell-based PDE4 assay was described using the PDE4 gene transiently transfected into COS cells, and the PDE activity was measured with a radioimmunoassay kit in cell lysate. 8 Another cell-based assay that examined PDE5 was reported using the rat fetal lung fibroblast (RFL-6) cells and the PDE activity was measured by the scintillation proximity assay (SPA) in cellular lysates. 9 These cell-based PDE4 assays had complicated assay procedure and relatively limited screening throughput. Recently, a cell-based luciferase reporter gene assay using the cAMP responsive element (CRE) binding sequence was reported for the measurement of PDE4, PDE7, and PDE10 activities. [10] [11] [12] In general, reporter gene assays often cause shifts in measured compound activities and produce increased false positives in compound library screening due to a long cascade of signal transduction and reporter gene transcription/translation. Finally, a throughput-limited cell-based PDE4 assay using a cyclic nucleotide-gated (CNG) cation channel as a biosensor was reported. In this assay, PDE activity was detected using the calcium dye Fura-2 and electrophysiology (using the voltage-clamp method). [13] [14] [15] We report here the development and validation of a new high-throughput-compatible PDE assay using a HEK293 cell line coexpressing a constitutively active GPCR receptor as a driving force for cAMP production together with a CNG channel as a cAMP sensor in 1536-well plate format.
MATERIALS AND METHODS

Materials
A PDE4 cell line (TSHR-CNG-HEK293), a parental cell line (CNG-HEK293), and the membrane potential dye kit were obtained from BD Biosciences (Rockville, MD). The DMEM medium, DPBS, Lipofectamine™ 2000, Geneticin ® , trypsin-EDTA, and penicillin/streptomycin were purchased from Invitrogen (Carlsbad, CA). The fetal bovine serum (FBS) was purchased from HyClone (Logan, UT). Puromycin and the pCMV-IRES-PURO vector were obtained from Clontech (Palo Alto, CA). Forskolin, isoproterenol, and PDE inhibitors were purchased from Sigma-Aldrich (St. Louis, MO).
Establishment of stably transfected PDE4 cell line and cell culture
The cell-based PDE4 assay uses a TSHR-CNG-HEK293 cell line (BD ACTOne™) coexpressing a thyroid-stimulating hormone receptor (TSHR) with a CNG cation channel stably expressed. This cell line was generated by transfecting 2 μg of a pCMV-TSHR-IRES-PURO plasmid with 6.25 μl of Lipofectamine™ 2000 to the BD ACTOne™ CNG-HEK293 cells. After 18 to 22 hr at 37 °C in 5% CO 2 , the transfected cells were selected in DMEM media containing 10% FBS supplemented with 250 μg/ml Geneticin ® and 2 μg/ml puromycin. Selection media was changed every 3 to 4 days, and colonies were observed 2 to 3 weeks after selection. Isolated colonies were selected and transferred into 24-well plates containing 1 ml of DMEM plus 10% FBS supplemented with 250 μg/ml Geneticin ® and 1 μg/ml puromycin (as growth medium).
Cells were harvested when they reached 80% to 90% confluence. After detachment by trypsin-EDTA, cells were diluted in growth medium at 7 × 10 5 cells/ml and 100 μl/well of cell suspension was added to Biocoat 96-well poly-D-lysine-coated plates (BD Biosciences) and cultured for 16 to 24 hr. An equal volume of 1× ACTOne™ membrane potential dye solution was then added to each well and incubated for 1 hr. The known PDE4 inhibitor R020-1724 was added and the fluorescence intensity that reflected PDE4 activity was measured in a FlexStation plate reader (Molecular Devices, Sunnyvale, CA).
The clones with a signal-to-basal ratio larger than 2-fold were selected as candidate cell lines for follow-up analysis. The final cell line was selected based on the IC 50 and concentrationresponse values of RO 20-1724 that were closest to the values reported previously.
The TSHR-CNG-HEK293 cells were maintained in the culture medium containing DMEM, 10% FBS, 250 μg/ml Geneticin ® , 1 µg/ml puromycin, 50 U/ml penicillin, and 50 μg/ml streptomycin at 37 °C under a humidified atmosphere containing 5% CO 2 . The parental CNG-HEK293 cells (without TSH receptor) were maintained in the same medium without puromycin. Cells were passaged when they reached to 80% to 90% confluence.
Cell-based PDE4 assay
Cells were dispensed at a density of 1000 cells per well in black, clear-bottom, tissue culture-treated, 1536-well plates (Kalypsys, San Diego, CA) in 3 μl of assay medium containing DMEM, 2% FBS, 50 U/ml penicillin, and 50 μg/ml streptomycin and were incubated 24 hr at 37 °C with 5% CO 2 prior to compound screening; 3 μl/well of 1× membrane potential dye was added and incubated for 1 hr at room temperature. The library compounds in DMSO solution or the positive control, RO 20-1724 , was added at 23 nl/well with a pin-tool station (Kalypsys). After a 60-min incubation with compounds at room temperature, the assay plate was measured in an EnVision™ fluorescence plate reader (PerkinElmer, Woburn, MA) in bottom reading mode with an excitation of 535 (±20) nm and emission of 590 (±20) nm. A flying reagent dispensing (FRD) workstation (Aurora Discovery, San Diego, CA) was used to dispense cells and reagents to 1536-well plates. The Kalypsys pin-tool station was used to transfer 23-nl compounds in DMSO solution to the 1536-well assay plate. The final DMSO concentration in the assay plates was under 0.5%. During library screening, all plate manipulations were done on an automated robotic system (Kalypsys).
PDE4 enzyme assay
The PDE4 A1A enzyme assay in IMAP format has been described previously. 16 In brief, 2 μl per well of PDE4 A1A enzyme (BPS Bioscience, San Diego, CA ) mixture (containing a final concentration of 0.05 ng/μl enzyme, 10 mM Tris, pH 7.2, 10 mM MgCl 2 , 1 mM DTT, 0.05% NaN 3 , and 0.15% BSA) was dispensed to 1536-well black solid-bottom plates. The compounds (diluted in DMSO) were added using the Kalypsys pin-tool station at 23 nl/well and then plates were spun at 1000 rpm for 15 sec in a tabletop centrifuge. After a 5-min incubation at room temperature, 2 μl/well of 200 nM cAMP was dispensed to each well and the plates were spun at 1000 rpm for 15 sec. The assay plates were incubated for 40 min at room temperature followed by an addition of 4 μl/well of IMAP detection reagent (Molecular Devices). The plates were measured in a ViewLux™ plate reader (PerkinElmer) in fluorescence polarization detection format (excitation = 480 nm and emission = 540 nm) after 1 hr of incubation at room temperature.
Compound library
A collection of 2187 compounds including 1208 compounds of the Library of Pharmacologically Active Compounds (LOPAC, Sigma-Aldrich) and 979 compounds from Tocris (Bristol, UK) was screened against this cell-based PDE4 assay. The compounds were dissolved in DMSO at a concentration of 10 mM for all stock solutions. All compounds were serially diluted in DMSO at a ratio of the square root of 5 (1:2.236) to 15 concentrations in 384-well plates. Four sets of the interplate dilution plates were subsequently reformatted into 1 set of 1536-well plates with concentrations ranging from 0.13 μM to 10 mM. After 23-nl compound addition, final compound concentrations in the 6-μl assay volume were from 0.49 nM to 38.3 μM.
Data analysis
The primary screening data and curve fitting were analyzed using custom software developed at the NIH Chemical Genomics Center. The maximal inhibition (100% activity) was determined by the response of 30 μM RO 20-1724 and the basal response (0% activity) was measured by the DMSO control in both the enzyme and the cell-based PDE4 assays. In the counterscreen with the parental cell line, 10 μM forskolin and 30 μM RO 20-1724 were added to determine the maximal inhibition. The concentration responses of the compounds were analyzed using the methods described by Inglese and colleagues. 17 In brief, concentration-response data were fitted to a 4-parameter Hill equation by minimizing the residual error between the modeled and observed responses. Concentration-response curves were divided into 4 classes: Class 1 contained complete concentration-response curves and r 2 values > 0.9. Class 2 contained incomplete concentration-response curves lacking the lower asymptote and show r 2 values > 0.9. Class 3 curves were of the lowest confidence as they were defined by a single concentration point for the inhibition. Finally, Class 4 contained all inactive compounds that did not show any concentration-response curves. Curves were further subdivided based on efficacy, either >80% inhibition compared with the control as class 1.1 or partial efficacy >50% inhibition as class 1.2. Clustering analysis of active compounds from the primary screening was performed with Leadscope ® Hosted Client (Leadscope Inc., Columbus, OH). The results from other experiments were analyzed with Prism software (GraphPad, San Diego, CA).
RESULTS AND DISCUSSION
This cell-based PDE4 assay uses a stably transfected CNG cation channel 14 as a biosensor whose signal can be detected by a change in membrane potential (Fig. 1) . The PDE substrate, cAMP, is produced by adenylate cyclase (AC), which is stimulated by the constitutive activity of stably transfected TSH receptors coupling through the G αS subtype of the G-proteins. 18 Previous studies have demonstrated that the TSH receptor exhibits a moderate level of constitutive activity in the absence of ligand when it is overexpressed in mammalian cells. 19, 20 The constitutive activity of transfected TSH receptors in the PDE4 cell line maintained a moderate level of cAMP production. The continual cAMP production provides the basis for the measurement of PDE activity without addition of a TSH receptor agonist. In the absence of a PDE inhibitor, the moderate level of cAMP in this PDE4 cell line is rapidly hydrolyzed by endogenous PDEs, predominantly PDE4 in the host HEK293, 14, 21 and is counted as a baseline. In the presence of a PDE4 inhibitor, cAMP accumulates and the increased levels of cAMP bind to and open the CNG cation channels, resulting in an influx of cations including Na + and Ca 2+ . This cation influx triggers a cell membrane depolarization that can be quantified using a fluorescent membrane potential dye that does not require cell wash or medium change steps. 22 Thus, the inhibition of PDE activity can be monitored homogeneously in live cells with a standard fluorescence plate reader.
There are several advantages of this cell-based PDE4 assay compared with other previously reported assays. 9, 10, 23 First, this cell-based PDE4 assay does not require an addition of exogenous cAMP stimuli such as forskolin (an AC activator) or GPCR agonists, because the constitutive activity of cotransfected TSH receptor produces enough cAMP to generate a measurable signal in the presence of a PDE inhibitor. Second, detection with the membrane potential dye enables homogenous measurement of PDE activity compared with the use of Schematic diagram of the detection mechanism of the cellbased PDE4 assay. The thyroid-stimulating hormone (TSH) receptor was cotransfected in HEK293 cells with a modified cyclic nucleotide-gated (CNG) channel that serves as a biosensor of intracellular cAMP levels. This transfected TSH receptor has a low level of constitutive activity that stimulates adenylate cyclase (AC) to produce a small amount of cAMP. In the absence of a cyclic nucleotide phosphodiesterase (PDE) inhibitor, this small amount of cAMP is quickly hydrolyzed by PDE, preventing activation of the CNG cation channel. In the presence of a PDE inhibitor, the cAMP level rises, activating the CNG cation channel and resulting in membrane depolarization. A membrane potential dye is used to monitor the change in the membrane potential that is proportional to the inhibition of PDE by the PDE inhibitor. Fura-2 dye or voltage-clamp methods, which have lower throughput and require a cell-wash step during the experiments. Third, the assay protocol is substantially simplified and standard fluorescence plate readers can be used, making this assay suitable for miniaturization and high-throughput screening.
Cell density optimization. All our experiments were carried out in the miniaturized 1536-well plate format. The effect of cell density was first tested in the presence or absence of 30 μM (EC 100 ) RO 20-1724, a PDE4 inhibitor. Although the total fluorescence intensity in the presence of 30 μM RO 20-1724 increased with the increase of cell number from 500 to 3000 cells per well, the basal signal also elevated as cell density increased. We found that 1000 cells per well produced a 5.2fold signal-to-basal ratio, which was superior to other cell densities (Fig. 2) . Thus, 1000 cells per well was chosen as an optimal cell density in 1536-well plate format for subsequent experiments. We also found that DMSO, the solvent for all the compounds in our screening collection, had no significant effect on this assay at concentrations up to 2%, indicating high tolerance to DMSO for this cell-based PDE4 assay (data not shown).
Time course for PDE4 inhibitors. The time course of 30 μM RO 20-1724 treatment in the PDE4 cells was measured after compound addition every 10 min for 2 hr. We found that after the addition of RO 20-1724, the total fluorescence signal increased rapidly during the first 20 min followed by a slow increase to its peak at 60 min and a gradual decrease afterward. The basal signal did not change with incubation time (Fig. 3) . This result suggested that cAMP pools began to accumulate in the cells after the addition of RO 20-1724 and the assay signal reached equilibrium at approximately 60 min. Other PDE4 inhibitors (rolipram, milrinone, trequinsin, and etazolate) were examined over a 70-min time frame, and the response of all compounds except trequinsin leveled off after 20 to 30 min. Trequinsin showed a gradual increase of activity over 70 min with no plateau; however, an acceptable signal-to-basal ratio was observed after 20 min of exposure (data not shown).
The decrease of the fluorescent signal after 60 min might be caused by the dye leaking out of cells and/or cells becoming less healthy 2 hr after the membrane potential dye treatment (60 min of dye loading and 60 min of stimulation). Thus, the response of PDE inhibition is stable and can be measured between 30 and 60 min after compound addition. This provides sufficient time for a measurement with a standard fluorescence plate reader without requiring a kinetic measurement. RO 20-1724 activity. In the cell-based PDE4 assay, a constitutively active GPCR (TSHR) is used to drive the production of cAMP, theoretically making the addition of exogenous GPCR agonists or forskolin unnecessary. However, before using this assay to detect novel PDE inhibitors, we tested it directly by examining whether the activity of a known PDE inhibitor was affected by a GPCR agonist or AC activator. The activity of RO 20-1724 in the presence or absence of 10 nM (EC 80 ) TSH was measured in the PDE4 cell line as well as in the parental cell line stimulated by 200 nM forskolin (EC 80 ). In the PDE4 cell line, the IC 50 values of RO 20-1724 in the presence and absence of TSH stimulation were 1.72 μM and 2.39 μM, respectively. The basal response in the TSH stimulated cells was high due to the constitutive TSH receptor activity, which reduced the assay window (Fig. 4a) . Our results indicated that the potency of RO 20-1724 in the PDE4 cell line remained the same regardless of whether the TSH stimulation was added but that the basal signal was much lower without TSH stimulation (Fig. 4a) . In the parental cell line, RO 20-1724 alone did not produce any measurable response (Fig  4b) , indicating that its activity in the PDE4 cell line was dependent on TSH receptor activity. The IC 50 values of RO 20-1724 in the parental cell line with forskolin stimulation was 1.44 μM (Fig. 4c) , similar to that determined from the PDE4 cell line. These results demonstrated that the potency of RO 20-1724 determined in this cell-based PDE4 assay without the stimulation by an exogenous agonist was very similar to the potency determined in the experiments stimulated by the GPCR agonist or forskolin. The lack of requirement for a GPCR agonist or AC activator in this assay has several advantages, including cost and time saving in assay optimization, improved consistency, and less possibility of receptor desensitization, which occurs in many GPCRs including the TSH receptor, 24,25 when exposed to high concentrations of agonists.
TSH and forskolin effects on
Compound library screening. A collection of 2187 compounds, most of which had a known pharmacological action, was screened in both the PDE and the parental cell lines. All compounds were titrated at 15 concentrations and the screen was performed in the quantitative high-throughput screening (qHTS) format 17 As described in Table 1 , 1000 cells per well (3-μl cell suspension) were dispensed into 1536-well assay plates and incubated at 37 °C and 5% CO 2 in a cell culture incubator for 24 hr, followed by addition of 3 μl of membrane potential dye per well and incubation at room temperature for 60 min to allow dye equilibration across the cell membrane, as recommended by the membrane potential dye manufacturer. The 15 compound dilutions were then added to the assay plates using a pin-tool at 23 nl/well, incubated for 60 min at room temperature, and fluorescence intensity was measured in a standard fluorescence plate reader at 530-nm excitation and 590-nm emission. The entire experimental process required reagent additions only, without the need for cell washing or medium aspiration, and was thus easily performed by both a robotic screening system and a semi-automated workstation. Figure 5a shows the 1536-well format plate map; columns 1 to 4 are used for controls and columns 5 to 48 for experimental compounds. In a test screening with a DMSO plate, the signal-to-basal ratio was 3.9-fold, coefficient of variation (CV) was 10.5%, and Z′ factor was 0.50 ( Fig. 5b) , indicating acceptable performance in 1536-well plate format. These assay statistics (signal-to-basal ratio, CV, and Z′ factor) were very similar in the parental cell line (data not shown). We found that Z′ factor was less than 0.5 (0.2-0.4) in some plates during the compound library screening. This might be due to the use of HEK293 cells, which exhibit reduced attachment on the assay plate after dye treatment and subsequently may have caused an increase in the variation between wells. Use of poly-D-lysine-coated plates might be able to improve the cell attachment and thus reduce the variation between wells; however, the 1536-well plates would need a customized coating of poly-D-lysine and this was not available at the time of screening. Recently, a similar HEK293 cell line assayed in non-poly-Dlysine-coated 1536-well plates was used in a successful qHTS campaign for GPCR agonist screening. The occasional low Z′ factor numbers were also found in some assay plates; however, several novel agonists were identified and confirmed from the screen. 26 The screening results from the parental cell line were used to eliminate the nonspecific and false positive compounds including fluorescent compounds, cAMP pathway signal activators (such as endogenous GPCR ligands, forskolin, etc). A total of 35 active compounds with a potency of less than 10 μM and a curve class of 1.1 or 1.2 17 with maximal inhibition greater than 50% were identified in the PDE4 cell line screen; of these, 17 were also active in the parental cell line. Many of the 17 compounds active in both cell lines have known actions in the cAMP signaling pathway (i.e., forskolin analogs, isoproterenol, etc.) whereas others are likely fluorescent compounds. Parallel screening of a parental cell line is therefore an effective method for eliminating the false positive compounds in this cell-based PDE4 assay.
Among the 18 remaining compounds, 11 were PDE inhibitors as defined by the compound providers ( Table 2) . The other 7 actives were reordered and tested in both PDE4 and parental cell lines, as well as in a PDE4 enzyme assay ( Table 3 ). The activities of 4 of 7 compounds were confirmed in both PDE4 cell line and PDE4 enzyme assay, and they were not active in the parental cell line. Among these 4 confirmed compounds, arctigenin was an inhibitor of MKK1 and IkBa phosphorylation and was also previously reported as a putative PDE inhibitor. 27 The other 3 confirmed compounds were all xanthine derivatives that were reported as classical adenosine receptor antagonists as well as inhibiting PDE activity. [28] [29] [30] [31] Among the 3 unconfirmed compounds, CB 34 was a peripheral benzodiazepine receptor agonist that was also active in both PDE and parental cell lines in the retests, although in the primary screen it was not classified as active in the parental cell line due to its borderline activity. The activities of the 2 other hits were not confirmed in the retests ( Table 3 ). Both of the compounds exhibited borderline activity in the primary screen with weak potency and low efficacy. None of these 3 compounds (CB 34, muscarine chloride, or terfenadine) exhibited PDE inhibitory activity in the purified PDE4 enzyme assay. Hence, 4 of 7 compounds were confirmed as PDE inhibitors in both the PDE4 cells and the PDE4 enzyme assay, whereas the activities of other 3 compounds were not confirmed due to the nonspecific action in cells or marginal activity. All primary screen results can be viewed in the PubChem database (AID: 607, http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=607).
Activities of known PDE inhibitors. The selectivity and potency of the PDE inhibitors (as defined by the compound providers) from the cell-based PDE4 assay and counter-screen in the parental cell line are summarized in Table 2 . All PDE4 specific inhibitors showed IC 50 values in the cell-based PDE4 assay within a 10-fold window to those reported elsewhere. For example, the IC 50 values for RO 20-1724, (S)-(-)-rolipram, trequinsin, and etazolate were 1.0, 0.1, 3.2, and 9.9 μM, respectively, from this cell-based PDE4 assay, and they showed either no activity or very weak activity in the parental cell line (Fig. 6) . Other compounds exhibited higher or lower potencies than reported values; this may be due to differences in the experimental conditions used in different laboratories (such as enzyme subtype, instrumentation, reagents, data normalization, etc). The activities of 5 nonselective PDE inhibitors including ibudilast, IMBX, 1,3-dipropyl-7-methylxanthine, and pentoxifylline in this assay were also within similar ranges of those reported in the literature ( Table 2) . The inhibitors specific to other PDE subtypes showed either no activity or very weak activity in this PDE assay. For example, vinpocetine, a PDE1 inhibitor with 20 μM reported IC 50 , showed only a 20% response 6 continued) at 33.3 μM in both the PDE and the parental cell lines. These results suggest that PDE4 is the predominant PDE enzyme type present in HEK293 cells, consistent with literature reports. 14, 21 
CONCLUSION
We have developed and validated a cell-based PDE4 assay in a 1536-well plate format. Cell-based PDE4 activity can be determined with a membrane potential dye in a standard fluorescence plate reader; most false positives are easily eliminated by a parallel screen or a counter-screen of the parental cell line. The simplicity of this assay indicates that it is suitable for high-throughput screening of large compound libraries in a 1536-well format to identify novel cell-permeable PDE4 inhibitors. Preliminary results also suggest that this cell-based PDE4 assay strategy can be extended to other PDEs types, either by heterogonous expression of other PDEs in the TSHR-CNG-HEK293 cell line, or by utilizing this biosensor in cell lines expressing high levels of other PDE family members. 6 continued) 
